Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

 
   By Jennifer Corbett Dooren 
   Of  
 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
06/23 PFIZER : Global Latanoprost Sales Market 2017 - Pfizer, Jamp Pharma, Laboratoire..
06/23 NOVARTIS : NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIF..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 HERE’S WHAT’S MOVING NOV : NVS) and Kamada Ltd (NASDAQ:KMDA)
06/23 NOVARTIS : Kisqali® (ribociclib) receives positive CHMP opinion as first-line tr..
06/23 NOVARTIS : data shows half of eligible Ph+ CML-CP patients remain in Treatment-f..
06/23 NOVARTIS : pivotal CTL019 6-month follow-up data show durable remission rates in..
06/22 NOVARTIS : combination targeted therapy Tafinlar® + Mekinist® receives FDA appro..
06/22 NOVARTIS : Medicxi launches first $300m late-stage life sciences fund Medicxi Gr..
06/22 AMGEN : AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will..
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/23 Novartis' CAR-T candidate CTL019 shows sustained remission rates in mid-stage..
06/23 FDA OKs combination of Novartis' Tafinlar + Mekinist for BRAF V600E-positive ..
06/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 23, 2017
06/22 Artificial Intelligence Is The Real Thing For Pharma And Medtech
06/22 Drug stocks rally on GOP draft of healthcare bill
Advertisement
Financials ($)
Sales 2017 48 383 M
EBIT 2017 11 853 M
Net income 2017 7 439 M
Debt 2017 15 455 M
Yield 2017 3,28%
P/E ratio 2017 25,94
P/E ratio 2018 22,85
EV / Sales 2017 4,98x
EV / Sales 2018 4,76x
Capitalization 225 386 M
More Financials
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 82,4 $
Spread / Average Target -4,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS12.96%225 386
JOHNSON & JOHNSON18.42%367 520
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
SANOFI14.27%123 860
More Results